SECsense Logo

Gyre Therapeutics, Inc. 8-K Report: Year-End Insights & Updates

$GYRE
Form 8-K
Filed on: 2025-01-06
Source
Gyre Therapeutics, Inc. 8-K Report: Year-End Insights & Updates

Based on the provided section of the financial report, here are the key information and insights extracted:

  1. Company Information:
  • Name: Gyre Therapeutics, Inc.
  • CIK (Central Index Key): 0001124105
  • Exchange: NASDAQ
  • Ticker Symbol: GYRE
  • Address: 12770 High Bluff Drive, Suite 150, San Diego, CA 92130
  • Phone Number: 619-949-3681
  1. Filing Details:
  • Form Type: 8-K (Current Report)
  • Filing Date: December 31, 2024
  • Entity Type: Corporation
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 000-51173
  • EIN (Employer Identification Number): 56-2020050
  1. Reporting Period:
  • Start Date: December 31, 2024
  • End Date: December 31, 2024
  • The report appears to be for a single day, suggesting it may contain information about a significant event or update.
  1. Security Information:
  • Class of Securities: Common Stock

Insights:

  • The filing is an 8-K form, which typically indicates that significant corporate events or changes have occurred, warranting disclosure to investors.
  • The company is publicly traded on NASDAQ under the ticker GYRE, suggesting it is subject to rigorous SEC reporting requirements.
  • The specified date for the report (December 31, 2024) indicates it is likely providing timely information regarding year-end financials or other critical company developments.

This summary encapsulates the essential aspects of the financial report provided, highlighting the company's identity, reporting details, and implications for stakeholders.